Rutgers New Jersey Medical School, The State University of New Jersey, 90 Bergen Street, Newark, NJ, 07103, USA.
Curr Allergy Asthma Rep. 2018 Jul 10;18(9):45. doi: 10.1007/s11882-018-0799-1.
The profile of biologic therapies for asthma is growing rapidly. We discuss how to match the proper pediatric patient with the most effective therapy.
Currently available biologic therapies are most effective in patients with T2 high asthma. Newer drugs are currently being studied which target TSLP and interleukin 33. These newer drugs may provide options for asthmatics who do not respond to the current anti-IgE, anti-IL5, and anti-IL4/13 therapies. Asthma is a heterogeneous disease which can be driven by different inflammatory mediators in different patients. To select the most effective biologic therapy for a pediatric patient, the asthma phenotype must first be determined. The steep cost of biologics limits their use, which makes proper pairing of patient to therapy even more crucial. Presently, several therapies exist for T2 high asthma, but it is hoped in the future that development of drugs effective for T2 low asthmatics will be available as well.
哮喘的生物疗法种类迅速增加。我们讨论如何将合适的儿科患者与最有效的治疗方法相匹配。
目前可用的生物疗法在 T2 高型哮喘患者中最有效。目前正在研究靶向 TSLP 和白细胞介素 33 的新型药物。对于那些对当前的抗 IgE、抗 IL5 和抗 IL4/13 治疗没有反应的哮喘患者，这些新型药物可能提供了选择。哮喘是一种异质性疾病，在不同患者中可能由不同的炎症介质驱动。为了为儿科患者选择最有效的生物治疗方法，首先必须确定哮喘表型。生物制剂的高昂成本限制了它们的使用，这使得患者与治疗方法的正确配对更加关键。目前，针对 T2 高型哮喘有几种治疗方法，但希望未来也能开发出针对 T2 低型哮喘有效的药物。
